The drug slows the decline in lung function, the leading cause of death for those with cystic fibrosis.
SHARE:
Thousands of patients who suffer from cystic fibrosis will now get access to a new drug on the NHS in England.
Vertex Pharmaceutical and NHS England reached an agreement to provide Orkambi and two other drugs to around 5,000 people.
Orkambi slows the decline in lung function, the most common cause of death for people with cystic fibrosis, and can be given to children as young as two.
It comes after a three year disagreement between the pharmaceutical firm and the NHS over the cost of the drug.
The deal also includes expanded access to the drugs Symkevi and Kalydeco, but cannot be used until a patient is 12 years old.
NHS chief executive Simon Stevens said the deal was a “long hoped-for moment”, while Health Secretary Matt Hancock said the deal was “great value for money” for the NHS.
Some wonderful news this morning: We’ve agreed a deal to provide Orkambi and other lifesaving Cystic Fibrosis drugs on the NHS. Huge thanks to the many campaigners who have worked so hard, and to Vertex & the NHS. #OrkambiNowhttps://t.co/6mM1YLL6EN
There is estimated to be over 100,000 people who have cystic fibrosis in the UK.
It is a genetic condition which causes lung infections and problems digesting food.
There is currently no cure, with only half of sufferers living to the age of 32.
Submitted Article
Headline
Short Headline
Standfirst
Published Article
HeadlineCystic fibrosis sufferers to get access to new drug in England
Short HeadlineNew drug for English cystic fibrosis sufferers
StandfirstThe agreement also expands the availability of two other dugs.
Thousands of patients who suffer from cystic fibrosis will now get access to a new drug on the NHS in England.
Vertex Pharmaceutical and NHS England reached an agreement to provide Orkambi and two other drugs to around 5,000 people.
Orkambi slows the decline in lung function, the most common cause of death for people with cystic fibrosis, and can be given to children as young as two.
It comes after a three year disagreement between the pharmaceutical firm and the NHS over the cost of the drug.
The deal also includes expanded access to the drugs Symkevi and Kalydeco, but cannot be used until a patient is 12.
NHS chief executive Simon Stevens said the deal was a “long hoped-for moment”, while Health Secretary Matt Hancock said the deal was “great value for money” for the NHS.
Some wonderful news this morning: We’ve agreed a deal to provide Orkambi and other lifesaving Cystic Fibrosis drugs on the NHS. Huge thanks to the many campaigners who have worked so hard, and to Vertex & the NHS. #OrkambiNowhttps://t.co/6mM1YLL6EN
There is estimated to be over 100,000 people who have cystic fibrosis in the UK.
It is a genetic condition which causes lung infections and problems digesting food.
There is currently no cure, with only half of sufferers living to the age of 32.
Thousands of patients who suffer from cystic fibrosis will now get access to a new drug on the NHS in England.
Vertex Pharmaceutical and NHS England reached an agreement to provide Orkambi and two other drugs to around 5,000 people.
Orkambi slows the decline in lung function, the most common cause of death for people with cystic fibrosis, and can be given to children as young as two.
It comes after a three year disagreement between the pharmaceutical firm and the NHS over the cost of the drug.
The deal also includes expanded access to the drugs Symkevi and Kalydeco, but cannot be used until a patient is 12 years old.
NHS chief executive Simon Stevens said the deal was a “long hoped-for moment”, while Health Secretary Matt Hancock said the deal was “great value for money” for the NHS.
Some wonderful news this morning: We’ve agreed a deal to provide Orkambi and other lifesaving Cystic Fibrosis drugs on the NHS. Huge thanks to the many campaigners who have worked so hard, and to Vertex & the NHS. #OrkambiNowhttps://t.co/6mM1YLL6EN
Internationally renowned for transforming her life into confessional art, the exhibition offers an intimate and unapologetic glimpse into one of Britain’s most influential contemporary artists.
As e-bike riders weave through London’s busiest junctions, red lights are increasingly treated as optional. One software engineer says the problem may be baked into how hire firms charge users
